Dr. Pathak is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
265 Cohasset Rd
Chico, CA 95926Phone+1 530-332-4700Fax+1 530-893-6906
Education & Training
Tower HealthResidency, Internal Medicine, 2013 - 2016
Nepal Medical CollegeClass of 2011
Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology
Certifications & Licensure
CA State Medical License 2020 - 2026
CT State Medical License 2017 - 2022
PA State Medical License 2013 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 8 citationsSecond primary malignancy in acute promyelocytic leukemia: a Surveillance, Epidemiology and End Results database study.Smith Giri, Ranjan Pathak, Madan Raj Aryal, Paras Karmacharya, Vijaya Raj Bhatt
Future Oncology. 2017-07-07 - 50 citationsAssociation of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features.Ranjan Pathak, Sarah B. Goldberg, Maureen E. Canavan, Jeph Herrin, Jessica R. Hoag
JAMA Oncology. 2020-11-01 - 42 citationsMeta-Analysis of Efficacy and Safety of Rivaroxaban Compared With Warfarin or Dabigatran in Patients Undergoing Catheter Ablation for Atrial FibrillationMadan Raj Aryal, Anene Ukaigwe, Anil Pandit, Paras Karmacharya, Rajesh Pradhan
The American Journal of Cardiology. 2014-08-15
Journal Articles
- Adjuvant Chemotherapy in Patients with Early-Stage Non–Small Cell Lung Cancer—ReplyRanjan Pathak, MD, JAMA Oncology
- Association of Survival with Adjuvant Chemotherapy Among Patients with Early-Stage Non–Small Cell Lung Cancer with vs Without High-Risk Clinicopathologic FeaturesRanjan Pathak, MD, JAMA Oncology
Press Mentions
Apixaban Doesn't Appear to Boost Bleeding in Kidney DiseaseNovember 26th, 2014
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
